aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Lyfebulb is dedicated to accelerating innovation for chronic disease patients by bridging patient communities with industry. The organization focuses on providing a strong voice to individuals living with chronic diseases, recognizing that patients and their care partners are uniquely positioned to offer valuable insights and solutions. Founded by Dr. Karin Hehenberger, Lyfebulb offers programs such as the Entrepreneur Circle and Ambassador initiatives to foster community engagement and collaboration.
Lyfebulb has made significant strides in connecting patients with industry leaders, driving innovation in chronic disease management. The organization has successfully created platforms for patient-driven insights and solutions, enhancing the quality of life for those affected by chronic illnesses. Through its various initiatives, Lyfebulb has established itself as a key player in the healthcare innovation space, making a tangible impact on the lives of chronic disease patients worldwide.
Operating Status
Active
Ownership Type(s)
Private
Main Product(s)
Patient Support
Technology
Community
Tags
Healthtech
Revenue Type(s)
Consulting
Customer Type(s)
Consumers, Enterprise, Non-Profit
Geographic Exposure
Global
When was Lyfebulb founded?
Lyfebulb was founded in 2014.
Where is Lyfebulb’s headquarters located?
Lyfebulb’s headquarters is located in New York City, NY, US.
How many employees does Lyfebulb have?
Lyfebulb has 27 employees as of Feb 4, 2024.
Add Comparison
Total Employees Over Time
27
As of Feb 2024
Lyfebulb Address
New York City,
New York
10065
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts